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Abstract
Background: Sedative, hypnotic, anxiolytic and opioid medicament (SO) use and its relation to
tobacco smoking and alcohol risk drinking is largely unknown. Prevalence data for SO intake and
its co-occurrence with tobacco smoking and alcohol risk drinking considering age are presented.
Methods: Random general population sample of individuals aged 20–79 drawn from a mixed rural
and urban area in Germany (Study of Health in Pomerania, SHIP). All medicament intake during the
past 7 days prior to the interview was assessed according to the Anatomical Therapeutic Chemical
classification as part of an interview conducted in a health examination center.
Results: Among men, 3.0%, and among women 5.0% took SO. The proportion of SO users was
higher (odds ratio 1.9; 95% confidence interval 1.1–3.4) whereas the proportions of current
cigarette smokers and alcohol risk drinkers without SO use were lower among individuals aged
60–79 compared to those aged 20–39. The proportion of individuals with smoking, alcohol risk
drinking or SO use was also lower among those aged 60–79 compared to the 20–39 year olds.
Conclusion: Although proportions of SO users in older adult age are higher than in younger adult
age there are less subjects with any of the 3 substance use behaviors at older adult age compared
to age 20–39.
Background
Little is known about (1) sedative, hypnotic, and anxio-
lytic (SHA), particularly benzodiazepine, and about (2)
opioid medicament use behavior in general adult popula-
tions. Both substance groups, SHA and opioids taken
together (SO) are related to health disorders, including
dependence, abuse, intoxication, and withdrawal [1].
Benzodiazepines have been shown to be the most preva-
lent substance taken among mental health-related drugs
in a general population sample aged 65 or older in Can-
ada [2]. In France, a telephone survey study of the general
population aged 18 or older revealed that 7.5% used ben-
zodiazepines and altogether 11.5% used drugs against
"anxiety, stress, to sleep or to relax [3]."
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Generally, there are two alternative approaches to collect
data on medicament use in general population studies.
The first is to ask for medicament use for specific pur-
poses, e. g. as a sleeping aid. The second approach
involves asking for any medicament use irrespective of its
purpose. Limitations of asking for medicament use by
purpose are that (1) those consumers are not considered
who take psychotropic medicines without having knowl-
edge of the indication or effect of the substance and the
potential dependence-related consequences of its intake
and (2) consumers who might intentionally conceal non-
medical use of substances. Asking for any medicament
consumption or collecting medicament package data has
the advantage to potentially reduce reporting bias,
although this approach does not allow to separate non-
medical from medical use.
Evidence is needed about the co-occurrence of SO use
with tobacco smoking and alcohol risk drinking in the
adult general population since data revealed higher mor-
bidity risks for co-occurrent smoking and risk drinking
than might be expected from the sum of risks of single
substance use [4,5]. The common addictive nature of the
substances makes it useful to describe whether there is co-
occurrent use and to what extent and in which subgroups
of the sample to a particular high degree. Co-use of these
substances may be relevant for explaining common dis-
eases. A co-occurrence might be explained by intentions
to regulate body sensations such as upward and down-
ward regulation of mood or use of different drugs for the
same end. Alcohol and SO consumption might be inter-
dependent because some of their effects, such as sedation,
are similar [cf. [6]]. But SO consumption might be pre-
ferred because it is less obvious in the public. In the 1991
to 1993 US National Household Survey on Drug Abuse
respondents with daily alcohol use had higher odds for
prescription drug nonmedical use than individuals with
less than daily alcohol use [7]. In a region of France, a
postal survey of the general population aged 18 to 74
revealed that 28.6% smoked, 8.6% had excessive alcohol
consumption, and 16.8% used medicaments for sleeping,
against tiredness, against nervousness or anxiety [8]. In
the US National Survey on Drug Use and Health more cur-
rent smokers and more individuals with frequent binge
drinking in the past two weeks were among benzodi-
azepine users than among non-users [9].
Contrary to SO use, tobacco smoking and alcohol risk
drinking is less frequent in older than in younger adult age
according to survey data, both among male and female
users [10]. Data from Germany revealed that the propor-
tion of current smokers among ever smokers is lower
among older adult age groups than among younger adult
age groups [11]. Older respondents in France included
lower proportions of smokers but higher proportions of
psychotropic medicament users [8]. Major shortcomings
of this study included that medicaments were assessed
with respect to their purpose; no data about the co-occur-
rence of different substance use behaviors were provided
and that the survey had a response proportion of only
44%. Taken together, we lack evidence about SO use and
its co-occurrence with tobacco smoking and alcohol risk
drinking from general population samples that include
young and older adult age.
The aim of this paper is to present, firstly, prevalence data
about SO use stratified by gender, age, education, income,
utilization of medical care, and a screening of psychiatric
diagnoses. Secondly, the co-occurrence of SO use with
current tobacco smoking and alcohol risk drinking will be
analyzed. We hypothesized that (1) among smokers and
alcohol risk drinkers, particularly among subjects who
smoke and additionally drink alcohol in a risky way, more
SO users may be found than among individuals who are
nonsmokers and non-alcohol problem drinkers, and (2)
in young and middle adult age there is a predominance of
cigarette smoking and alcohol risk drinking whereas in
older adult age SO use is more prevalent than current cig-
arette smoking and alcohol risk drinking. Accordingly, the
use of any of the three substances is expected to be equally
distributed over young, middle and older adult age.
Methods
Sample
The sample comprised all subjects from a random popu-
lation sample drawn in a north-eastern German region.
The sample is representative for the population of 212157
residents aged 20 – 79 in an area of West Pomerania in
North-Eastern Germany. There were 7008 eligible individ-
uals within this age range, stratified by 5-year strata and
gender from residents' registration office files, in which
every resident has to be registered by law, in three cities of
20,000 to 55,000 inhabitants and 29 surrounding towns
and villages in West Pomerania. Of all eligible individu-
als, a total of 4310 (2193 females, 2117 males; response
proportion: 68.8%), after having given written informed
consent, took part in a health examination. It was carried
out at the university hospital [12]. Among the partici-
pants, 20 had no or unfinished interview or incomplete
data or refused to answer the questions for recent use of
medication, leaving 4290 subjects as our final sample. The
project was approved by the human research ethics com-
mittee of the Medical School at the University of Greif-
swald. Data were collected between 1997 and 2001. In the
eastern German area in which the data were gathered
there was no substantial illegal drug use known until 1990
due to the fact that the borders had been strictly control-
led and there had been no purchasing power that might
be interesting for an illegal drug market.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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Assessments
Medicament intake was assessed using the information of
the drug packages if they were available. Otherwise the
respondent provided information on the name of the spe-
cific medicament. The study aims and single parts of the
health examination were explained to the individuals in
brief in the invitation letter and in detail as a first step after
having entered the health examination center. Subjects
who had agreed to participate in the study were informed
to bring the prescription sheets and the packages of all
medications they had been taking during the past 7 days
prior to the health examination. Subjects were asked as
part of the interview: "During the last seven days: have
you taken any medication such as tablets, drops, supposi-
tories, or have you had any injection?" If this was the case,
every compound was recorded. If available, the German
central pharmaceutics number, a unique identification
code, was recorded for linking it with the German drug
databases. Compounds were identified and categorized
using the Anatomical Therapeutic Chemical (ATC) classi-
fication [13] by local pharmacists who worked with two
drug databases, which are widely used by pharmacists and
scientists in Germany: the database (version Nov 30,
2001) of the Research Institute of the Health Insurance
company AOK (WidO) and the database of the Federal
Pharmacists' Association (ABDA, version Dec 1, 1999).
Both databases together cover every compound that is
licensed and available in Germany.
Due to the fact that not all participants brought their med-
icament packages with them and due to insufficient infor-
mation provided by the respondent, not all compounds
could be fully identified. When the pharmaceutics
number was not provided the drug name was searched in
the drug databases. The best fitting medicament was
selected (called "proxy drug"), leading to a proxy pharma-
ceutics number. If no choice was possible for a specific
drug only the ATC code was selected. Seventy two medica-
ments remained unidentified, mainly due to non-specific
or false drug names given by the respondent. These medi-
caments were excluded from the analyses, not however
the persons. Compounds with real or proxy pharmaceuti-
cal number could, in most of all cases, be linked directly
to the ABDA database. If only the ATC but not the phar-
maceutical number was available the ATC was used as a
link.
SO were defined in accordance with SHA and licit opioids
according to the Diagnostic and Statistical Manual of
mental disorders (DSM-IV) [1]. The single medicaments
were classified according to the ATC [13]. SHA included
barbiturates, benzodiazepines or benzodiazepine-like
substances, carbamates, and other sedatives, hypnotics or
anxiolytics in accordance with DSM-IV. We used medica-
ments other than SO in our analysis, not however vitamin
or mineral substituents, tonics (ATC groups A11, A12,
A13) or hormonal contraceptives (ATC G03AA, G03AB,
G03AC).
Cigarette smoking was assessed by interview questions.
Current cigarette smokers were those who answered "Yes"
to the question "Do you currently smoke cigarettes?".
Alcohol consumption was assessed based on two inter-
view questions: "How much beer, wine, and spirits did
you drink at the last working day (but not Friday)?" and
"How much beer, wine, and spirits did you drink at the
last weekend, i. e. Saturday and Sunday?" We calculated
grams pure alcohol by the multiplying volume % (4.8 for
beer, 11.0% for wine, and 33.0% for spirits) with 0.794
and with liters of each drink. The product provided the
grams pure alcohol. Risk drinking was defined as drinking
more than 20 gr pure alcohol per day among women, and
more than 30 gr pure alcohol per day among men [14].
School education, income, utilization of outpatient med-
ical care including the specialization of the treating physi-
cian during the past 12 months and inpatient medical care
including the number of days in hospital in the past 12
months was also assessed by computer-assisted personal
interview. School education was divided into 3 groups of
years of school education (<10, 10, > 10 years) according
to the German school system. These 3 groups give infor-
mation about the older and the younger study partici-
pants although the proportion of residents with 10 or
more years school education has increased in Germany
since the 1960ies. Income per month was estimated by
income per household divided by the number of its mem-
bers.
We screened for psychiatric disorders using the CID-S, a
12-item questionnaire for depressive, anxiety, somato-
form, and substance use disorders during lifetime [15].
The following screening diagnoses were assessed: somato-
form disorder (no, yes), number of anxiety disorders
(0–5), number of depressive disorders (0–2), mania (no,
yes), alcohol use disorders (no, yes), medication abuse
(no, yes), illegal drug consumption (no, yes). The CID-S
questions are taken from the Composite International
Diagnostic Interview (CIDI) [16], German version [17].
The CID-S development study revealed that among indi-
viduals who affirmed at least one CID-S item, the sensitiv-
ity ranged between 79.0 and 95.2% for the single current
disorders according to the Diagnostic and Statistical Man-
ual (DSM-IV) [18] covered by the CIDI [15].
Statistical analysis
The statistical analysis included SHA and opioid use. SO
use in total was calculated by firstly assessing opioid
intake. SHA use was assessed among all individuals with-
out opioid intake. Other medicament users were defined
as using neither SHA nor opioids but other medicaments.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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We defined the substance use pattern by separating five
alternative groups of individuals: (1) current cigarette
smokers without alcohol risk drinking and without SO
use, (2) current cigarette smokers who were also alcohol
risk drinkers but did not use SO, (3) alcohol risk drinkers
who were neither current cigarette smokers nor SO users,
(4) all SO users, (5) individuals who were neither current
cigarette smokers nor alcohol risk drinkers nor SO users.
Proportions and multivariable regression models were
estimated using SVY procedures in the Stata software
package [19] as the complex sampling strategy in this
study required adjustments in calculating the parameter
estimates and standard errors. We calculated likelihood
ratio chi2 tests. According to medicament use, chi2 tests
were first calculated for differences among all individuals
including users of SHA, opioids, other medicaments, and
individuals who did not use any medicaments. Second,
chi2 tests were calculated to test for differences among the
three subgroups of medicament users only (SHA, opoio-
ids, other medicaments). We used the effect size measure
Cohen's w [20] to analyze bivariable associations. Accord-
ing to Cohen [20], we interpreted values .10 to < .30 as
indicating a small and .30 to < .50 a medium effect size.
Odds ratios and 95% confidence intervals (CI) are
reported for multinomial logistic regression and for
binary logistic regression analysis. Age was grouped into
young (20 to 39 years), middle (40 to 59 years), and older
adult age (60 to 79 years) since national data from Ger-
many had revealed that proportions of current smokers
among male ever smokers were 64.1% at the age of 40–49
and 37.2% at age 60–69 compared to 95.5% among those
younger than 20 years [11]. Further variables used for the
data analysis were: school education (<10, 10, > 10 years),
monthly income per household member (tertiles: < 950
€, 950 – < 1440 €, > 1440 €), outpatient care during the
last 12 months prior to the health examination (neurolo-
gist or psychiatrist, GP but not neurologist or psychiatrist,
other but neither neurologist, psychiatrist nor GP, no out-
patient contact).
Results
Prevalence and determinants of SO use
Among the sample, 3.8% used SO, and 57.4% used med-
icaments other than SO. Among men, 3.0%, and among
women 5.0% used one or more SO. There were 0.1% (6)
barbiturate users, 2.5% (109) benzodiazepine users,
0.02% (1) carbamate user, 0.2% (7) users of other SHA,
and 1.1% (49) opioid users. Among men, 3.0%, and
among women 5.0% used SO (Table 1).
SO use was not more prevalent among smokers or alcohol
risk drinkers than among subjects who neither smoked
nor drank alcohol in a risky way. Among male current cig-
arette smokers who also drank alcohol in a risky way,
there were 2.3% and among female current cigarette
smokers who also drank alcohol in a risky way there were
4.8% who also used SHA or opioids (Table 2). Smokers
and risk drinkers were 1.6 to 3.7% among men and 4.7 to
5.1% among women. No associations were found
between smoking or alcohol risk drinking and SO use:
None of the smoker and risk drinker subgroups of the
sample was different from subjects who had no medica-
ment use as the reference group with respect to SO use in
a multinomial logistic regression analysis after controlling
for age and sex (Table 3)
In a further step, SO use was analyzed with respect to med-
ical treatment. All SO users except one had contact to a
physician during the past 12 months prior to the inter-
view. Among individuals who had consulted a neurolo-
gist or a psychiatrist during the past 12 months, 10.6%
took SHA and 3.4% took opioids (Table 4). Among those
without a psychiatric screening diagnosis, less than 2%
used SO compared to 8.2% among those with 3 or more
psychiatric screening diagnoses.
Women did not have higher odds for SHA or opioid use
than men after adjustment for age, school education,
income, outpatient care by a neurologist or psychiatrist,
inpatient treatment, and psychiatric screening diagnoses,
and using all subjects with use of other medicaments as
the comparison group (Table 5). Since women and men
did not differ according to the proportions of SHA or opi-
oid users when the effect size measure Cohen's w was
taken as the criterion we performed the multivariable data
analysis without stratification for gender. Among individ-
uals aged 60 to 79 higher odds were found for SHA intake
when users of medicaments other than SO are the com-
parison group. School education of less than ten years was
associated with higher odds for SHA intake than more
than ten years school education when users of medica-
ments other than SHA or opioids were the comparison
group. Individuals with 3 or more psychiatric diagnoses
had higher odds for SHA or opioid intake compared to
users of other medicaments.
Substance use pattern
Among men, 50.9% had one or more substance use risk
behaviors, among women 35.3% (Table 6). Effect sizes
were largest for the differences by age groups. Among men
aged 60 to 79, there were 15.2% current cigarette smokers
without SO use and 4.7% SO users in contrast to 50.8%
current smokers without SO use and 2.0% SO users at age
20 to 39. Women aged 60 to 79 included 8.8% current cig-
arette smokers without SO use and 8.4% SO users in con-
trast to 41.5% current cigarette smokers without SO use
and 2.1% SO users among women at age 20 to 39. Accord-
ing to the number of substance use behaviors among
tobacco smoking, alcohol risk drinking, and SO use,BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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34.1% of the sample revealed one, and 8.9% two or three
of the substance use risks. Among all men who practiced
at least one of the 3 substance use behaviors, 6.0% used
SO, and among women 14.1% used SO (Chi2 223.1; df 3;
p < 0.001; w .34). The data revealed that the proportions
of individuals with at least one substance use risk behav-
ior were lower in older than in younger age groups:
among the young adults, 56.7%, among the middle adult
age individuals, 46.8%, and in the older age group 26.3%
disclosed at least one substance use behavior (Chi2 281.0;
df 2; p < 0.001; w .25).
Women revealed lower odds than men for substance use
patterns without SO use, not however for SO use after
adjustment for age, school education, income, outpatient
care rendered by a neurologist or psychiatrist, inpatient
treatment, and psychiatric screening diagnoses (Table 7).
Therefore, we conducted further analysis without stratifi-
cation for gender. Those aged 60 to 79 had an OR of 1.9
(CI 1.1–3.4) for SO use in contrast to lower odds for cur-
rent smokers or alcohol risk drinkers compared to indi-
viduals who were neither current cigarette smokers nor
alcohol risk drinkers nor SO users. Opposite findings for
all SO users on the one hand side and smokers without
SO use on the other hand side were also revealed for out-
patient care provided by a neurologist or psychiatrist.
Those with the lowest education had higher odds for
smoking and for SO use compared to those who did not
use any of the three substances. Substance use in total,
current cigarette smoking, alcohol risk drinking or SO use,
was lower among individuals at age of 40 or above com-
pared to individuals younger than 40 years.
Discussion
There are four main findings. First, when taking SO use,
tobacco smoking and alcohol risk drinking together, the
substance-related health risk of the population is high
throughout all age groups and in both genders. Second,
the data suggest that there is no higher odds ratio for SO
use among smokers and among alcohol risk drinkers
compared to those who neither smoke nor drink alcohol
in a risky way. Third, the data confirm findings from pre-
vious studies that show particularly high proportions of
SO users at older age groups. Fourth, the proportion of SO
users is lower than the proportion of current cigarette
smokers or alcohol risk drinkers when all age groups are
considered. The hypothesis is supported that in older
adult age more SO use is present than in younger age
groups, among men and among women. However, sub-
jects with intake of any of the 3 substances were unequally
distributed across younger, middle, and older adult age.
Table 1: Sedatives, hypnotics or anxiolytics (SHA), opioids, and other medicaments users
Men Women
SHAa Opioidsb Other 
medicaments
No 
medicaments
Total SHAa Opioidsb Other 
medicaments
No 
medicaments
Total
Total 2.1 0.9 55.8 41.2 100.0 3.5 1.5 60.6 34.4 100.0
All individuals Chi2 27.5; df 3; p < 0.001; w .08
All medicament users Chi2 6.6; df 2; p <.05; w .05
Age (years)
20–39 1.5 0.5 31.5 66.5 100.0 1.0 1.1 39.9 58.0 100.0
40–59 1.0 1.2 47.7 50.1 100.0 3.0 1.7 62.6 32.8 100.0
60–79 3.8 0.9 82.7 12.6 100.0 6.8 1.6 80.3 11.3 100.0
All individuals Chi2 490.5; df 6; p < 0.001; w .46 Chi2 367.5; df 6; p < 0.001; w.40
All medicament users Chi2 7.7; df 4; ns; w .08 Chi2 13.7; df 4; p < 0.01; w .10
Education (years)
< 10 2.9 0.8 69.6 26.7 100.0 5.8 1.8 74.4 18.0 100.0
10 1.8 1.1 43.2 53.9 100.0 2.0 1.6 51.0 45.4 100.0
> 10 1.0 0.6 51.4 47.0 100.0 2.0 0.3 57.5 40.3 100.0
All individuals Chi2 149.5; df 6; p < 0.001; w .26 Chi2 181.1; df 6; p < 0.001; w.28
All medicament users Chi2 5.4; df 4; ns; w .07 Chi2 13.4; df 4; p < 0.01; w .09
Row per cent. Among the total sample, opioid users were identified. Among all non-opioid users, SHA users were identified.
Among all individuals who used neither opioids nor SHA, other medicament users were identified.
Chi2: Likelihood chi2-test, significance levels: p < 0.001, p < 0.01, p <  0.05, ns not significant.  
df degrees of freedom.
w Cohen's w [20].
a Sedatives, hypnotics, or anxiolytics: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, N05CE, 
N05CM, N05CX [13] during the past 7 days prior to the health examination.
b ATC groups A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the past 7 days 
prior to the health examination.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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We did not find an association between current smoking
or alcohol risk drinking with SHA or opioid use, neither
in the total sample nor in single age groups. This finding
indicates that there is no such relation with psychotropic
medicine use in this sample as is known from smoking
and risk drinking and the respective hypothesis is rejected.
One explanation might be that SHA and opioid use were
by far more rare than smoking in this sample. Easy avail-
ability of cigarettes and alcohol might add to that. On the
other hand, particularly for elderly women a preference
Table 2: Sedatives, hypnotics or anxiolytics (SHA), opioids, and other medicaments users
Men Women
SHAa Opioidsb Other 
medicaments
No 
medicaments
Total SHAa Opioidsb Other 
medicaments
No 
medicaments
Total
Total 2.1 0.9 55.8 41.2 100.0 3.5 1.5 60.6 34.4 100.0
Current smokers, alcohol 
risk drinkers
Smoker, risk drinker 1.9 0.4 37.9 59.8 100.0 4.8 0.0 58.7 36.5 100.0
Smoker, non risk drinker 2.7 0.4 43.9 52.9 100.0 2.7 2.1 47.3 47.9 100.0
Non smoker, risk drinker 1.6 0.0 55.9 42.6 100.0 3.8 0.9 57.6 37.7 100.0
Non smoker, non risk 
drinker
2.2 1.5 65.1 31.2 100.0 3.7 1.4 65.6 29.3 100.0
All individuals Chi2 119.9; df 9; p < 0.001; w .24 Chi2 65.0; df 9; p < 0.001; w .17
All medicament users Age 
20–39
Chi2 11.9; df 6; ns; w .09 Chi2 5.9; df 6; ns; w .06
Current smokers, alcohol 
risk drinkers
Smoker, risk drinker 2.4 0.8 30.4 66.4 100.0 0.0 0.0 50.0 50.0 100.0
Smoker, non risk drinker 2.1 0.5 35.2 62.2 100.0 1.1 1.8 38.6 58.5 100.0
Non smoker, risk drinker 1.2 0.0 29.4 69.4 100.0 0.0 2.9 38.2 58.8 100.0
Non smoker, non risk 
drinker
0.5 0.5 29.6 69.4 100.0 1.1 0.5 40.4 58.0 100.0
All individuals Chi2 6.1; df 9; ns; w .09 Chi2 6.0; df 9; ns; w .09
All medicament users Age 
40–59
Chi2 3.4; df 6; ns; w .12 Chi2 5.3; df 6; ns; w .12
Current smokers, alcohol 
risk drinkers
Smoker, risk drinker 1.7 0.0 37.6 60.7 100.0 8.3 0.0 63.9 27.8 100.0
Smoker, non risk drinker 1.3 0.6 37.9 60.1 100.0 4.2 3.2 51.8 40.7 100.0
Non smoker, risk drinker 0.0 0.0 54.2 45.8 100.0 2.0 0.0 65.3 32.6 100.0
Non smoker, non risk 
drinker
1.0 2.5 53.3 43.2 100.0 2.2 1.5 66.0 30.3 100.0
All individuals Chi2 32.0; df 9; p < 0.001; w .20 Chi2 18.8; df 9; p < 0.05; w .15
All medicament users Age 
60–79
Chi2 13.4; df 6; p < 0.05; w .16 Chi2 11.6; df 6; ns; w .15
Current smokers, alcohol 
risk drinkers
Smoker, risk drinker 0.0 0.0 74.1 25.9 100.0 0.0 0.0 100.0 0.0 100.0
Smoker, non risk drinker 6.2 0.0 70.8 22.9 100.0 5.0 0.0 73.3 21.7 100.0
Non smoker, risk drinker 4.3 0.0 82.8 12.9 100.0 13.0 0.0 69.6 17.4 100.0
Non smoker, non risk 
drinker
3.4 1.3 85.1 10.2 100.0 6.7 1.9 81.4 10.0 100.0
All individuals Chi2 22.8; df 9; p < 0.01; w .17 Chi2 11.6; df 9; ns; w .13
All medicament users Chi2 8.4; df 6; ns; w .10 Chi2 4.3; df 6; ns; w .08
Row per cent. Among the total sample, opioid users were identified. Among all non-opioid users, SHA users were identified.
Among all individuals who used neither opioids nor SHA, other medicament users were identified.
Chi2: Likelihood chi2-test, significance levels: p < 0.001, p < 0.01, p <  0.05, ns not significant.
df degrees of freedom.
w Cohen's w [20].
a Sedatives, hypnotics, or anxiolytics: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, N05CE, 
N05CM, N05CX [13] during the past 7 days prior to the health examination.
b ATC groups A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the past 7 days 
prior to the health examination.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
Page 7 of 12
(page number not for citation purposes)
for SHA might be expected. However, there was no strong
evidence for this.
The proportion of individuals who showed one or more
risk behaviors among tobacco smoking, alcohol risk
drinking and SO use is tremendously high among those
Table 4: Sedatives, hypnotics or anxiolytics (SHA), opioids, and other medicaments users
SHAa Opioidsb Other medicaments No medicaments Total
Outpatient care 12 months
Neurologist or psychiatrist 10.6 3.4 72.2 13.8 100.0
GP, not neurologist or psychiatrist 2.2 1.0 61.9 34.9 100.0
Other, not neurologist or psychiatrist 1.6 1.1 59.3 38.0 100.0
No 0.0 0.2 18.8 81.0 100.0
All individuals Chi2 557.9; df 6; p < 0.001; w .37
All medicament users Chi2 66.7; df 6; p < 0.001; w .17
Inpatient care (days)
No 2.5 1.0 56.2 40.2 100.0
1–9 2.4 2.4 64.5 30.7 100.0
10 or more 5.9 2.2 73.7 18.2 100.0
All individuals Chi2 89.8; df 6; p < 0.001; w .14
All medicament users Chi2 8.7; df 6; ns: w .06
Psychiatric disorders (number)
0 1.3 0.4 53.4 44.9 100.0
1 – 2 2.3 1.1 58.8 37.8 100.0
3 or more 5.8 2.4 64.3 27.6 100.0
All individuals Chi2 133.6; df 6; p < 0.001; w .18
All medicament users Chi2 47.7; df 4; p < 0.001; w .14
Row per cent. Among the total sample, opioid users were identified. Among all non-opioid users, SHA users were identified.
Among all individuals who used neither opioids nor SHA, other medicament users were identified.
Chi2: Likelihood chi2-test, significance levels: p < 0.001, ns not significant.
df degrees of freedom.
w Cohen's w [20].
a Sedatives, hypnotics, or anxiolytics: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, N05CE, 
N05CM, N05CX [13] during the past 7 days prior to the health examination.
b ATC groups A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the past 7 days 
prior to the health examination.
Table 3: Associations between smoking and alcohol risk drinking with medicament use; multinomial logistic regression analysis
Comparison group: no medicaments
SOa use Other medicament use
Smokers, risk drinkers
Non smoker, non risk drinker Ref Ref
Smoker, non risk drinker 1.0 (0.8–1.4) 0.7 (0.6–0.8)
Non smoker, risk drinker 0.7 (0.4–1.0) 0.9 (0.7–1.2)
Smoker, risk drinker 1.0 (0.4–2.1) 0.7 (0.6–0.8)
Gender
Men Ref Ref
Women 2.4 (1.6–3.5) 1.5 (1.3–1.8)
Age (years)
20–39 Ref Ref
40–59 2.7 (2.1–3.6) 2.3 (2.0–2.5)
60–79 18.3 (13.7–24.6) 11.1 (9.3–13.2)
Odds ratios (95%-confidence intervals).
Current smokers: current cigarette smokers, alcohol risk drinking according to [14],
a Sedatives, hypnotics, or anxiolytics or opioids: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, 
N05CE, N05CM, N05CX, A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the 
past 7 days prior to the health examination.
Ref: Reference category.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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younger than 40 with 66.5% among men and 48.2%
among women. Substance use in older age is a prevalent
health risk behavior, although the proportion of sub-
stance users at age 60 to 79 is less than half the respective
proportion at age 20 to 39, both in women and men. We
do not know the specific reasons for this difference. Selec-
tive mortality, smoking cessation and changes in alcohol
consumption may have caused this finding.
The proportions of SHA or opioid users seem to be lower
than those found in other research [3]. This might be due
to differences in data collection methods or characteristics
of the samples, such as age ranges. Furthermore, our data
do not confirm that the group of benzodiazepine users
contains more current smokers or alcohol risk drinkers
than non-users [9]. The data confirm findings of a higher
proportion of SO users in older than in young adult age
[3,8] and they compare with data that revealed high pro-
portions of benzodiazepine consumers among the elderly
[2]. However, no differences by age were present when SO
users are compared to individuals with other medicament
intake except for SHA at age 60 to 79. The adjusted OR for
SO users compared to individuals without smoking, with-
out alcohol risk drinking and without SO use is 1.9 with a
lower confidence bound close to 1 (CI 1.1 to 3.4). The
bivariable statistics revealed higher proportions of indi-
viduals with SHA or opioid use in higher age groups
among all medicament users only for women. Even in
older adult age, smoking and alcohol risk drinking are the
main substance use risk behaviors among men whereas
among women the proportion with SO use is close to the
proportion of current smokers and alcohol risk drinkers.
Less educated individuals and those with the lowest
income had higher odds for current cigarette smoking and
for SO use after adjustment compared to those with the
Table 5: Associations between gender, age and sedative, hypnotic or anxiolytic and opioid medication use; multinomial logistic 
regression analysis
Comparison group: no medicament use Comparison group: other medicament use
SHAa Opioidsb Other medicament SHAa Opioidsb
Gender
Men Ref Ref Ref Ref Ref
Women 2.0 (1.3–2.9) 2.0 (1.1–3.8) 1.5 (1.3–1.7) 1.3 (0.9–1.9) 1.4 (0.8–2.4)
Age (years)
20–39 Ref Ref Ref Ref Ref
40–59 2.5 (1.7–3.8) 2.6 (1.3–4.9) 2.3 (2.1–2.5) 1.1 (0.7–1.6) 1.1 (0.6–2.1)
60–79 25.7 (19.3–34.1) 11.5 (5.0–26.5) 10.9 (9.0–13.3) 2.3 (1.8–3.1) 1.0 (0.4–2.5)
Education (years)
> 10 Ref Ref Ref Ref Ref
10 1.6 (0.99–2.6) 2.9 (1.2–7.4) 1.0 (0.8–1.2) 1.7 (1.0–2.7) 3.0 (1.2–7.8)
< 10 2.3 (1.5–3.6) 2.5 (0.9–6.7) 1.3 (1.0–1.5) 1.9 (1.2–3.0) 2.0 (0.7–5.8)
Income c (Euro)
> 1440 Ref Ref Ref Ref Ref
950 – < 1440 0.7 (0.5–0.98) 0.8 (0.4–1.5) 0.8 (0.6–0.99) 0.9 (0.5–1.5) 1.0 (0.5–2.4)
< 950 1.0 (0.7–1.4) 1.1 (0.7–1.8) 0.8 (0.6–0.9) 1.4 (0.96–1.9) 1.5 (0.8–2.7)
Outpatient care
not neurologist or psychiatrist Ref Ref Ref Ref Ref
neurologist or psychiatrist 8.6 (4.5–16.4) 3.8 (2.5–5.7) 2.6 (2.0–3.3) 3.4 (2.0–5.7) 1.5 (0.97–2.3)
Inpatient care (days)
no Ref Ref Ref Ref Ref
1–9 1.0 (0.5–2.1) 3.3 (1.4–7.6) 1.5 (1.2–1.9) 0.7 (0.3–1.4) 2.2 (1.0–5.0)
10 or more 2.4 (1.4–4.2) 3.0 (1.5–5.9) 2.0 (1.5–2.7) 1.2 (0.7–1.9) 1.5 (0.9–2.7)
Psychiatric disorders, number
0 Ref Ref Ref Ref Ref
1 – 2 2.3 (1.2–4.6) 2.4 (1.2–4.5) 1.4 (1.3–1.5) 1.7 (0.9–3.2) 1.7 (0.9–3.2)
3 or more 6.7 (3.5–13.0) 6.5 (4.2–9.9) 2.0 (1.7–2.3) 3.4 (1.8–6.5) 3.2 (2.1–5.0)
Odds ratios (95%-confidence intervals).
a Sedatives, hypnotics, or anxiolytics: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, N05CE, 
N05CM, N05CX [13] during the past 7 days prior to the health examination.
b ATC groups A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the past 7 days 
prior to the health examination.
c Household-income divided by number of persons per household.
Ref: Reference category.B
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) Table 6: Substance use patterns
Men Women
Current 
smokers, no 
alcohol risk 
drinking, no 
SOa use
Current 
smokers, 
alcohol risk 
drinking, no 
SOa use
No current 
smokers, 
alcohol risk 
drinking, no 
SOa use
All SOa 
users
No 
substance 
use
Total Current 
smokers, no 
alcohol risk 
drinking, no 
SO* use
Current 
smokers, 
alcohol risk 
drinking, no 
SOa use
No current 
smokers, 
alcohol risk 
drinking, no 
SOa use
All SOa 
users
No 
substance 
use
Total
Total 20.3 12.5 15.1 3.0 49.1 100.0 22.9 2.8 4.6 5.0 64.7 100.0
Chi2 330.5; df 4; p < 0.001; w .27
Age (years)
20–39 30.9 19.9 13.8 2.0 33.5 100.0 37.8 3.7 4.6 2.1 51.8 100.0
40–59 20.6 15.8 19.8 2.2 41.7 100.0 21.6 4.1 5.9 4.7 63.7 100.0
60–79 11.7 3.5 11.6 4.7 68.4 100.0 8.6 0.2 3.0 8.4 79.8 100.0
Chi2 281.1; df 8; p < 0.001; w .36 Chi2 249.2; df 8; p < 0.001; w .32
Education (years)
< 10 19.2 9.6 12.4 3.7 55.0 100.0 15.7 1.1 3.2 7.6 72.5 100.0
10 23.4 16.4 16.9 2.9 40.4 100.0 30.7 3.3 4.2 3.6 58.2 100.0
> 10 14.8 9.5 17.4 1.6 56.8 100.0 15.9 4.9 10.1 2.3 66.9 100.0
Chi2 64.2; df 8; p < 0.001; w .17 Chi2 123.0; df 8; p < 0.001; w .24
Incomeb (Euro)
< 950 25.3 17.3 13.8 3.3 40.3 100.0 30.1 4.8 2.8 4.5 57.8 100.0
950 – < 1440 20.1 11.0 16.0 2.6 50.3 100.0 22.2 1.4 5.4 4.4 66.6 100.0
> 1440 15.1 9.5 16.4 2.8 56.3 100.0 15.1 2.0 6.2 5.8 70.9 100.0
Chi2 56.9; df 8; p < 0.001; w .17 Chi2 73.9; df 8; p < 0.001; w .19
Outpatient care
Neurologist or psychiatrist 14.0 6.0 13.5 14.0 52.4 100.0 15.3 2.4 3.5 13.9 64.8 100.0
GP, not neurologist or psychiatrist 20.4 11.8 15.1 2.0 50.7 100.0 22.9 2.7 4.3 4.4 65.7 100.0
Other, not neurologist or psychiatrist 15.9 10.7 17.8 3.7 51.8 100.0 21.5 2.4 7.2 1.7 67.2 100.0
No 28.1 21.1 13.4 0.3 37.1 100.0 41.3 4.9 4.9 0.0 49.0 100.0
Chi2 108.0; df 12; p < 0.001; w .26 Chi2 103.0; df 12; p < 0.001; w .22
Inpatient care (days)
no 20.9 12.8 15.5 2.6 48.3 100.0 23.4 2.8 4.9 4.5 64.4 100.0
1–9 20.4 13.4 14.1 2.8 49.3 100.0 23.0 4.0 3.4 6.8 62.8 100.0
10 or more 15.5 9.3 11.9 7.2 56.2 100.0 17.7 1.2 2.4 9.2 69.5 100.0
Chi2 18.1; df 8; p < 0.05; w .10 Chi2 14.9; df 8; ns; w .08
Psychiatric disorders (number)
0 19.9 12.9 16.2 0.9 50.1 100.0 21.9 2.2 4.1 2.8 69.0 100.0
1 – 2 21.7 11.7 14.4 2.8 49.4 100.0 26.4 1.5 4.6 4.0 63.6 100.0
3 or more 18.7 13.1 13.8 7.9 46.5 100.0 20.0 4.7 5.1 8.3 61.9 100.0
Chi2 46.8; df 8; p < 0.001; w .16 Chi2 47.4; df 8; p < 0.001; w .15
Row percent.
Chi2: Likelihood chi2-test, significance levels: p < 0.001, p < 0.05, ns  not significant.
df degrees of freedom.
w Cohen's w [20].
Current smokers: current cigarette smokers, alcohol risk drinking according to [14],
a Sedatives, hypnotics, or anxiolytics or opioids: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, N05CE, N05CM, N05CX, A07DA52, N01AH, N02AA, 
N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the past 7 days prior to the health examination.
b Household-income divided by number of persons per household.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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highest school education and the highest income respec-
tively. The data suggest that proportions of SO users are
higher among those with a larger number of psychiatric
disorders, not however the proportions of individuals
with other SP.
Substance use patterns are different with respect to gen-
der, age, education, and utilization of outpatient medical
care. Women have substantially less alcohol risk drinking
whereas they do not differ from men according to SO use.
While there are less current smokers, with or without co-
occurrent alcohol risk drinking, there are more SO users at
age 60 – 79 compared to those younger than 40. Several
explanations might hold for this finding. On the one
hand side concerns about one's health status might be
responsible for quitting smoking and alcohol risk drink-
ing among the older individuals, whereas on the other
hand problems of quality of life at older age, such as how
to cope with sleeplessness, might stimulate SO use. How-
ever, there are differences by education and income indi-
cating that individuals with less education presented
higher proportions of smokers, alcohol risk drinkers and
SO users. One reason might be that substance use and
morbidity is higher in subpopulations with low compared
to those with high socioeconomic status. One subgroup
among SO users might be those who are in neurological
or psychiatric outpatient treatment.
Our data do not allow conclusions according to non-med-
ical or medical SO use. The data revealed more SO use
Table 7: Associations with substance use patterns; multinomial logistic regression analysis
Comparison group: None of the 3 substances taken Any substance usea
Current smokers, no 
alcohol risk drinking, 
no SOb use
Current smokers, 
alcohol risk drinking 
no SOb use
No current smokers, 
alcohol risk drinking 
no SOb use
All SOb usersc
Gender
Men Ref Ref Ref Ref Ref
Women 0.7 (0.6–0.8) 0.13 (0.10–0.18) 0.2 (0.16–0.26) 1.1 (0.8–1.5) 0.4 (0.39–0.5)
Age (years)
20–39 Ref Ref Ref Ref Ref
40–59 0.5 (0.4–0.6) 0.7 (0.56–0.99) 1.1 (0.9–1.5) 1.2 (0.7–2.1) 0.6 (0.5–0.8)
60–79 0.14 (0.10–0.18) 0.09 (0.06–0.15) 0.5 (0.3–0.6) 1.9 (1.1–3.4) 0.2 (0.17–0.3)
Education (years)
> 10 Ref Ref Ref Ref Ref
10 1.9 (1.5–2.5) 1.5 (1.0–2.1) 0.9 (0.7–1.2) 2.2 (1.2–4.2) 1.5 (1.3–1.7)
< 10 2.3 (1.7–3.1) 1.5 (1.0–2.3) 0.8 (0.5–1.1) 2.3 (1.2–4.4) 1.5 (1.3–1.8)
Incomed (Euro)
> 1440 Ref Ref Ref Ref Ref
950 – < 1440 1.3 (1.0–1.6) 1.1 (0.8–1.5) 1.1 (0.8–1.4) 0.9 (0.6–1.4) 1.1 (0.96–1.3)
< 950 1.4 (1.2–1.8) 1.6 (1.2–2.2) 0.9 (0.6–1.1) 1.4 (0.9–2.1) 1.3 (1.1–1.4)
Outpatient care
not neurologist or psychiatrist Ref Ref Ref Ref Ref
neurologist or psychiatrist 0.7 (0.5–0.996) 0.5 (0.3–0.9) 0.9 (0.6–1.3) 2.9 (2.0–4.2) 1.0 (0.9–1.2)
Inpatient care (days)
No Ref Ref Ref Ref Ref
1–9 1.0 (0.7–1.4) 1.3 (0.8–2.1) 1.0 (0.6–1.5) 1.2 (0.6–2.2) 1.0 (0.8–1.3)
10 or more 0.9 (0.6–1.3) 1.0 (0.6–1.7) 0.8 (0.5–1.3) 1.4 (0.9–2.2) 1.0 (0.8–1.2)
Psychiatric disorders (number)
0 Ref Ref Ref Ref Ref
1 – 2 1.3 (1.1–1.5) 0.9 (0.6–1.2) 0.9 (0.7–1.2) 2.0 (1.2–3.3) 1.1 (0.8–1.7)
3 or more 1.1 (0.9–1.4) 1.4 (1.0–2.0) 1.0 (0.8–1.4) 4.2 (2.5–6.8) 1.3 (0.99–1.7)
a Logistic regression analysis for any of the 3 substances used versus none of the 3 substances used.
Odds ratios (95%-confidence intervals).
Current smokers: current cigarette smokers, alcohol risk drinking according to [14],
b Sedatives, hypnotics, or anxiolytics or opioids: ATC groups N01AF, N01AG, N03AA, N05CA, N05CB, N03AE, N05BA, N05CD, N05CF, N05BC, 
N05CE, N05CM, N05CX, A07DA52, N01AH, N02AA, N02AB, N02AC, N02AD, N02AE, N02AF, N02AG, N02AX, N02CX58 [13] during the 
past 7 days prior to the health examination.
c This group includes SO users with or without current smoking or alcohol risk drinking. All subgroups of SO users were taken together because of 
small cell frequencies.
d Household-income divided by number of persons per household.
Ref: Reference category.BMC Public Health 2007, 7:337 http://www.biomedcentral.com/1471-2458/7/337
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among individuals who had consulted a neurologist or a
psychiatrist during the past 12 months prior to the health
examination than among individuals without service use.
However, even among individuals in medical treatment,
there may have been non-medical use if they took the sub-
stances in larger amounts than prescribed. Moreover, we
could not identify the reasons for taking the substance
including use according to prescription only, abuse or
dependence on prescription drugs in conjunction with
illicit drug use or prescription drug use when illicit drugs
of choice were not available [21].
One objection against our measurement of substance use
patterns is that current smoking, alcohol risk drinking and
SO use may be comparable only in part. Differences in
availability of the substances must be considered. Neither
exists a standardization of the amount of toxic effects
which the individuals are exposed to across tobacco
smoke, alcohol and SO nor is there evidence of a standard
score according to their risk potential. Diseases caused by
tobacco smoking and alcohol risk drinking are largely
known, and there also exists evidence about dose-
response-relations. We know less from SO use. Our data
did not include how long and in which dose SO have been
taken. Guidelines for risks are available for alcohol con-
sumption [e.g. [14]] whereas for SO use it seems to be
largely unknown which lower limit exists for attributable
morbidity and mortality depending on the single drug.
There is some knowledge about the risk increase by the co-
occurrence of tobacco smoking and alcohol risk drinking
but we hardly know anything about how SO use interacts
with consumption of the other two substances. Further-
more, tolerance and total lifetime doses of exposure until
manifestation of disease that is attributable to the sub-
stance use may differ between men and women.
Further limitations of our study are: (1) The sample was
drawn in one region of Germany only. It is not represent-
ative for the whole country due to its low population den-
sity and different social structure. However, we assume
that this does not change the associations between smok-
ing alcohol risk drinking and potential confounders with
SO use as analyzed in this study. (2) No data about cur-
rent illicit drug use were available. (3) The sample
includes only individuals who were younger than 80 years
when the sample was drawn. Above that age there seem to
be less current smokers and alcohol risk drinkers whereas
SO use may be more prevalent than in the age range of our
sample [cf. [3,11,22]]. (4) In several cases the cell num-
bers were small. Thus, more significant differences may be
expected in a larger sample for SHA and for opioid use for
age, education and income, outpatient and inpatient care,
and number of psychiatric disorders (5) This is a cross-sec-
tional study. Thus, age cohort effects cannot be excluded.
(6) For each of the three substance use behaviors different
reporting bias may have been active, which is expected
high for alcohol drinking amounts and low for smoking
and SO use. The reason is that there were low health pol-
icy efforts to combat smoking and SO use at the time of
the data collection or before that time. A strength of the
present study is the data gathering of medicaments. This
might have added to the reduction of reporting bias. But
we may have missed some drugs. Recall bias may have
been active among those who did not bring their medica-
ment packages. Even among those who brought their
drugs, some may have missed single packages. Individuals
who had prescriptions actually may have not have taken
the medication. (7) We do not know the duration of med-
icament intake. (8) Beyond drugs, the data have been
gathered on grounds of self-statements and were not veri-
fied biochemically. However, other evidence suggests that
in population-based studies, there is no considerable risk
of denial which significantly influences the results [23].
Conclusion
SO use is less prevalent than tobacco smoking or alcohol
risk drinking in this general population sample. Although
the proportion of individuals with SO use was higher in
older than in younger adult age, any substance use among
current cigarette smoking, alcohol risk drinking or SO use,
was lower in older adult age than at age 20–39.
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